Ondine Biomedical Management
Management criteria checks 2/4
Ondine Biomedical's CEO is Carolyn Cross, appointed in Feb 2005, has a tenure of 20.25 years. total yearly compensation is CA$1.78M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 35.27% of the company’s shares, worth $17.98M. The average tenure of the management team and the board of directors is 2.8 years and 7.2 years respectively.
Key information
Carolyn Cross
Chief executive officer
CA$1.8m
Total compensation
| CEO salary percentage | 29.75% |
| CEO tenure | 20.3yrs |
| CEO ownership | 35.3% |
| Management average tenure | 2.8yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CA$2m | CA$529k | -CA$19m |
| Sep 30 2024 | n/a | n/a | -CA$17m |
| Jun 30 2024 | n/a | n/a | -CA$14m |
| Mar 31 2024 | n/a | n/a | -CA$14m |
| Dec 31 2023 | n/a | n/a | -CA$14m |
| Sep 30 2023 | n/a | n/a | -CA$17m |
| Jun 30 2023 | n/a | n/a | -CA$19m |
| Mar 31 2023 | n/a | n/a | -CA$19m |
| Dec 31 2022 | CA$892k | CA$476k | -CA$19m |
| Sep 30 2022 | n/a | n/a | -CA$37m |
| Jun 30 2022 | n/a | n/a | -CA$54m |
| Mar 31 2022 | n/a | n/a | -CA$52m |
| Dec 31 2021 | CA$699k | n/a | -CA$50m |
Compensation vs Market: Carolyn's total compensation ($USD1.30M) is above average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Carolyn's compensation has increased whilst the company is unprofitable.
CEO
Carolyn Cross
Ms. Carolyn M. Cross, C.F.A. & M.B.A., has been Chairman and Chief Executive Officer of Sinuwave Technologies Corporation since 2011. She is founder of Ondine Biomedical Inc. and had been its Chairman sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 20.3yrs | CA$1.78m | 35.27% $ 18.0m | |
| President | 21.1yrs | CA$1.54m | 0.80% $ 407.1k | |
| Non-Board Interim CFO | no data | no data | no data | |
| Vice President of Corporate Communications | 3.3yrs | no data | no data | |
| Vice President of Sales & Marketing | 2.3yrs | no data | no data | |
| Senior VP of Engineering & Operations | no data | no data | no data | |
| Corporate Controller & Company Secretary | 1.2yrs | no data | no data | |
| VP of Finance & Company Secretary | no data | no data | no data |
Experienced Management: OBIM.F's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.2yrs | CA$1.78m | 35.27% $ 18.0m | |
| President | 8.3yrs | CA$1.54m | 0.80% $ 407.1k | |
| Senior Independent Non-Executive Director | 3.5yrs | CA$133.29k | 0.047% $ 23.9k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Chairman of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Chairman of Medical Advisory Board | 7.2yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | CA$30.29k | no data | |
| Independent Chairman of the Board | 7.3yrs | CA$10.75k | 0.080% $ 40.7k | |
| Independent Non-Executive Director | 3.5yrs | CA$122.54k | 0.072% $ 36.6k |
Experienced Board: OBIM.F's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 13:50 |
| End of Day Share Price | 2025/04/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ondine Biomedical Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Simms | Arden Partners Plc. |
| David Dean | Cormark Securities Inc. |
| Charles Weston | RBC Capital Markets |